Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056297 · ClinicalTrials.gov registry record · Phase 3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
A Phase 3 study of Neutropenia, sponsored by X4 Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT06056297 is a Phase 3 study of Neutropenia that is actively recruiting participants, run by X4 Pharmaceuticals. The registered enrollment target is 176 participants, above the 63-participant average among 12 other Neutropenia trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06056297, a Phase 3 study of Neutropenia, is actively recruiting participants, sponsored by X4 Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mavorixafor
Study Locations (20)
California
- UC Irvine - Irvine
- Orso Health - La Jolla
- University of California, Los Angeles-UCLA - Los Angeles
- Orso Health - Torrance
Texas
- UT Southwestern Medical Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital/ Baylor College of Medicine - Houston
- Sarah Cannon Research Institute - Woodland
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Arizona
- Phoenix Children's Hospital - Phoenix
Florida
- University of Southern Florida - St. Petersburg
Georgia
- Children's Healthcare of Atlanta (CHOA) - Atlanta
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2024-06-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06056297
The ClinicalTrials.gov registry entry for NCT06056297 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 12 other Neutropenia trials with a reported enrollment target (179% higher). The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neutropenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06056297 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT06056297 about?
NCT06056297 is a clinical study titled "A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections". The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonst...
What is the current status of trial NCT06056297?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2024-06-06. Estimated completion is 2027-11.
What conditions does trial NCT06056297 study?
This clinical trial studies the following conditions: Neutropenia.
What interventions are being tested in trial NCT06056297?
The interventions under investigation include: Placebo (DRUG), Mavorixafor (DRUG).
Who is sponsoring clinical trial NCT06056297?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06056297 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neutropenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
COMPLETED · Phase 3
-
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
COMPLETED · Phase 3
-
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
COMPLETED · Phase 3
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
RECRUITING · Phase 1
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.